Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Ghobadloo, Shahrokh M ^a   Balcerzak, Anna K ^a   Gargaun, Ana ^a   Muharemagic, Darija ^a   Mironov, Gleb G ^a   Capicciotti, Chantelle J ^a   Briard, Jennie G ^a   Ben, Robert N ^a   Berezovski, Maxim V ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFREEZE PROTEIN; CRYOPROTECTIVE AGENT; GLYCOPEPTIDE; VIRUS LIKE PARTICLE VACCINE;

CELL CULTURE; CHEMISTRY; CRYOPRESERVATION; CRYSTALLIZATION; FREEZE DRYING; HERPES SIMPLEX VIRUS 1; HUMAN; MICROBIAL VIABILITY; VACCINIA VIRUS; VESICULOVIRUS;

ANTIFREEZE PROTEINS; CELLS, CULTURED; CRYOPRESERVATION; CRYOPROTECTIVE AGENTS; CRYSTALLIZATION; FREEZE DRYING; GLYCOPEPTIDES; HERPESVIRUS 1, HUMAN; HUMANS; MICROBIAL VIABILITY; VACCINES, VIRUS-LIKE PARTICLE; VACCINIA VIRUS; VESICULOVIRUS;

EID: 84905263437     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05903     Document Type: Article

References (39)

1. Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J. & Middaugh, C. R. Thermal stability of vaccines. J. Pharm. Sci. 92, 218-231 (2003). (Pubitemid 36169294)
2. Rexroad, J., Wiethoff, C. M., Jones, L. S. &Middaugh, C. R. Lyophilization and the thermostability of vaccines. Cell Preserv. Technol. 1, 91-104 (2002). (Pubitemid 36950491)
3. Kristensen, D., Chen, D. & Cummings, R. Vaccine stabilization: research, commercialization, and potential impact. Vaccine 29, 7122-7124 (2011).
4. Matthias, D. M., Robertson, J., Garrison, M. M.,Newland, S.&Nelson, C. Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine 25, 3980-3986 (2007). (Pubitemid 46616996)
5. Galazka, A., Milstien, J. & Zaffran, M. Thermostability of vaccines: Global programme for vaccines and immunization. World Health Organization. Geneva (1998).
6. Knezevic, I. Stability evaluation of vaccines: WHO approach. Biologicals 37, 357-359 (2009).
7. Vrdoljak, A. et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J. Controlled Release 159, 34-42 (2012).
8. Milstien, J. B., Galazka, A. M., Kartoglu, U. M. & Zaffran, M. Temperature sensitivity of vaccines. WHO Document Production Services, pp. 1-73. (2006).
9. Greenwood, B., Salisbury, D. & Hill, A. V. Vaccines and global health. Philos. T. R. Soc. B. 366, 2733-2742 (2011).
10. Dietz, V., Galazka, A., Van Loon, F. & Cochi, S. Factors affecting the immunogenicity and potency of tetanus toxoid: implications for the elimination of neonatal and non-neonatal tetanus as public health problems. Bull. World Health Organ. 75, 81 (1997).
11. Parato, K. A. et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20, 749-758 (2011).
12. Wang, G. et al. Eggshell-inspired biomineralization generates vaccines that do not require refrigeration. Angew. Chem. 124, 10728-10731 (2012).
13. Wang, G. et al. Rational design of thermostable vaccines by engineered peptideinduced virus self-biomineralization under physiological conditions. Proc. Natl. Acad. Sci. U. S. A. 110, 7619-7624 (2013).
14. Cary, Z. D.,Willingham, M. C. & Lyles, D. S. Oncolytic vesicular stomatitis virus Induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J. Virol. 85, 5708-5717 (2011).
15. Barber, G. N. VSV-tumor selective replication and protein translation. Oncogene 24, 7710-7719 (2005). (Pubitemid 41670673)
16. Lyles, D. S. & Rupprecht, C. E. in Fields Virology Vol. 1 (eds David M. Knipe & Peter M. Howley) Ch. 39, 1364-1408 (Lippincott Williams & Wilkins, 2007).
17. Balachandran, S. & Barber, G. N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50, 135-138 (2000).
18. Committee, R. D. A. Vol. December 3-4 (ed U.S. Department of Health and Human Services) (National Institutes of Health, Bethesda, 2008).
19. Committee, R. D. A. Vol. September 9-10 (ed U.S. Department of Health and Human Services) (National Institutes of Health, Bethesda, 2008).
20. Clarke, D. et al. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin. Immunopathol. 28, 239-253 (2006). (Pubitemid 44764280)
21. Geisbert, T. W. et al. Vesicular stomatitis virus-based ebola vaccine is welltolerated and protects immunocompromised nonhuman primates. PLoS Path. 4, e1000225 (2008).
22. Cobleigh, M. A., Buonocore, L., Uprichard, S. L., Rose, J. K. & Robek, M. D. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J. Virol. 84, 7513-7522 (2010).
23. Majid, A. M., Ezelle, H., Shah, S. & Barber, G. N. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J. Virol. 80, 6993-7008 (2006). (Pubitemid 44025198)
24. Jacobs, B. L. et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 84, 1-13 (2009).
25. Williams, K. A. Synthesis and Characterization of Monosaccharide-derived Low Molecular Weight Gelators PhD thesis, University of New Orleans, (2011).
26. Czechura, P., Tam, R. Y., Dimitrijevic, E., Murphy, A. V. & Ben, R. N. The importance of hydration for inhibiting ice recrystallization with C-linked antifreeze glycoproteins. Journal of the American Chemical Society 130, 2928-2929 (2008). (Pubitemid 351455951)
27. Harding, M. M., Anderberg, P. I. & Haymet, A. D. J. 'Antifreeze' glycoproteins from polar fish. Eur. J. Biochem. 270, 1381-1392 (2003).
28. Tachibana, Y. et al. Antifreeze glycoproteins: Elucidation of the structural motifs that are essential for antifreeze activity. Angew. Chem. Int. Ed. 43, 856-862 (2004). (Pubitemid 39256214)
29. Wilkinson, B. L. et al. Total synthesis of homogeneous antifreeze glycopeptides and glycoproteins. Angew. Chem. Int. Ed. 51, 3606-3610 (2012).
30. Pfannemüller, B. & Welte, W. Amphiphilic properties of synthetic glycolipids based on amide linkages. I. Electron microscopic studies on aqueous gels. Chem. Phys. Lipids 37, 227-240 (1985).
31. Fuhrhop, J. H., Schnieder, P., Boekema, E.&Helfrich, W. Lipid bilayer fibers from diastereomeric and enantiomeric N-octylaldonamides. J. Am. Chem. Soc. 110, 2861-2867 (1988).
32. Knight, C. A., Hallett, J. & DeVries, A. L. Solute effects on ice recrystallization: An assessment technique. Cryobiology 25, 55-60 (1988). (Pubitemid 18039792)
33. Jackman, J. et al.Assessing antifreeze activity of AFGP 8 using domain recognition software. Biochem. Biophys. Res. Commun. 354, 340-344 (2007). (Pubitemid 46161334)
34. Capicciotti, C. J. et al. Potent inhibition of ice recrystallization by low molecular weight carbohydrate-based surfactants and hydrogelators. Chem. Sci. 3, 1408-1416 (2012).
35. Tam, R. Y., Ferreira, S. S., Czechura, P., Chaytor, J. L. & Ben, R. N. Hydration index-A better parameter for explaining small molecule hydration in inhibition of ice recrystallization. J. Am. Chem. Soc. 130, 17494-17501 (2008).
36. Azizi, A. et al. Viral quantitative capillary electrophoresis for counting and quality control of RNA viruses. Anal. Chem. 84, 9585-9591 (2012).
37. Galasso, G. & Sharp, D. Virus particle aggregation and the plaque-forming unit. The Journal of Immunology 88, 339-347 (1962).
38. Kissmann, J. et al. Stabilization of measles virus for vaccine formulation. Hum. Vaccines 4, 350-359 (2008).
39. Das, P. Revolutionary vaccine technology breaks the cold chain. Lancet Infect. Dis. 4, 719 (2004).